Company*
(Symbol)

Product

Description

Indication

Status
(Date)


CANCER

AEterna Laboratories Inc. (Canada; AELA; TSE:AEL)

Neovastat

Antiangiogenic product

Metastatic refractory prostate cancer

Phase I/II study results in 48 patients confirmed Neovastat's safety profile and dose-related activity (6/27)

Amgen Inc.
(AMGN) and Praecis Pharmaceuticals Inc. (PRCS)

Abarelix

Gonadotropin-
releasing hormone antagonist

Prostate cancer

Phase III results demonstrated Abarelix's ability to reduce serum prostate-specific antigen and testosterone levels compared to standard hormone therapy (6/4)

Bioniche Life Sciences Inc. (Canada; TSE:BNC)

MCC

Mycobacterial cell wall technology

Carcinoma in situ of the bladder

Phase I/II study results showed a 59% complete response to MCC, and a 65% positive response (6/25)

Celgene Corp. (CELG)

Thalomid

Thalidomide; modulates levels of tumor necrosis factor-alpha

Metastatic colorectal cancer

Celgene initiated two studies evaluating the safety and efficacy of Thalomid in combination with Xeloda (6/1)

Cell Genesys Inc. (CEGE)

GVAX

Lung cancer vaccine

Lung cancer

Company initiated a second multicenter Phase I/II trial (6/21)

Corixa Corp. (CRXA)

Melacine

Vaccine consisting of lysed cells from two human melanoma cell lines combined with Corixa's Detox adjuvant

Stage II melanoma

Phase III data showed there was not a statistically significant improvement on disease-free survival, but among patients who express Class I major histocompatibility complex human leukocyte antigen A2 or C3 genes, Melacine does make a statistically significant improvement in disease-free survival (6/21)

Dendreon Corp. (DNDN)

Provenge

Vaccine that appears to delay tumor progression

Prostate cancer

Company initiated a Phase III trial (6/11)

Enzon Inc. (ENZN) and Schering- Plough Corp.

PEG-Intron

Injection; peginterferon alfa-2b

Chronic myelogenous leukemia

PEG-Intron did not meet the primary endpoint of non-inferiority in its study comparing it to Intron A (6/11)

Genta Inc. (GNTA)

Genasense

Antisense compound geared toward blocking the production of Bcl-2

Multiple myeloma and acute myeloid leukemia

In one study, Genasense decreased Bcl-2 protein in acute myeloid leukemia cells by 72 hours; in another study, it reduced Bcl-2 levels in myeloma cells; also, used in combination with Mylotarg, it increased cell death up to 63%, compared to treatment with Mylotarg alone (6/25)

ILEX Oncology Inc. (ILXO)

ILX-651 and NM-3

Synthetic pentapeptide analogue of dolastatin; orally active small molecule that inhibits angiogenesis by blocking the expression of vascular endothelial growth factor

Cancer

Company began enrollment in its Phase I trials (6/19)

Immunomedics Inc. (IMMU)

Bispecific antibody

Composed of half of an anti-CEA antibody linked to half of another antibody targeting a carrier with a therapeutic isotope attached to it

Cancer

Phase I/II data showed no toxicity after the therapeutic isotope was given (6/27)

Lorus Therapeutics
Inc.
(Canada;
OTC BB:LORFF;
TSE:LOR)

GTI-2501

Antisense compound

Solid tumors or lymphoma

Company began a Phase I trial (6/11)

Matrix Pharmaceutical
Inc.
(MATX)

IntraDose

Cisplatin/epinephrine injectable gel

Primary liver cancer

Began enrollment in a Phase II study (6/28)

Matrix Pharmaceutical Inc. (MATX)

IntraDose

Cisplatin/epinephrine injectable gel

Head and neck cancer

Company initiated a study of IntraDose used in combination with other chemotherapeutic

agents (6/21)

MediGene AG (Germany; Neuer Markt:MDG) and
Aventis Pharma
AG
(Germany)

¿

Vaccine based on gene transfer by adenoassociated viruses

Malignant melanoma

Companies started a Phase I/II trial (6/25)

MGI Pharma Inc. (MOGN)

Irofulven

Used in combination with Gemzar (gemcitabine hydrochloride)

Advanced cancers

Company initiated a Phase I trial (6/19)

Millennium Pharmaceuticals Inc. (MLNM)

LDP-341

Acts against cancer cells by blocking proteasome function

Chronic lymphocytic leukemia

Company initiated a Phase II trial of LDP-341; it also initiated Phase I trials testing it in combination with gemcitabine and irinotecan (6/15)

Novuspharma SpA (Italy; Nuovo Mercato:NOV)

BBR 3464

Novel tri-platinum complex

Advanced pancreatic cancer

Recruitment began for a Phase II trial (6/21)

Peregrine Pharmaceuticals Inc. (PPHM)

Cotara

Radiolabeled monoclonal antibody that binds to the necrotic core of tumors and uses beta-radiation to kill tumors from the inside out

Primary and unresectable cancers of the pancreas, liver, prostate or brain

Company presented Phase I/II results showing the drug was well tolerated and displayed positive results (6/26)

Protarga Inc.*

Taxoprexin DHA-paclitaxel

Synthetic small molecule made by chemically linking paclitaxel to the natural fatty acid docosahexaenoic acid

Advanced renal cell carcinoma

Company began a Phase II study (6/6)

Ribozyme Pharmaceuticals Inc. (RZYM) and Chiron Corp. (CHIR)

Angiozyme

Antiangiogenic; ribozyme that targets the high- affinity receptor for vascular endothelial growth factor

Metastatic colorectal cancer

Companies initiated treatment of the first patient in a Phase II trial (6/20)

Supergen Inc. (SUPG)

Rubitecan

Oral chemotherapy compound

Pancreatic cancer

Company completed patient enrollment for its second of three pivotal Phase III studies (6/12)

Telik Inc. (TELK)

TLK286

Small-molecule drug that targets tumors that overexpress GST P1-1

Non-small-cell lung cancer

Company started a Phase II trial (6/28)

Titan Pharmaceuticals Inc. (AMEX:TTP)

CeaVac

Monoclonal antibody that induces an immune response to the carcino- embryonic antigen

Advanced colorectal cancer

Company completed enrollment in its Phase III study of CeaVac (6/19)

CARDIOVASCULAR

Centocor Inc.*

Retavase and ReoPro

A clot-dissolving fibrinolytic agent and abciximab, an anticlotting agent

Heart attack

Phase III results evaluating half the dose of Retavase and a standard dose of ReoPro showed reduced complications, including the recurrence of heart attack and the need for urgent procedures to open coronary arteries (6/15)

Collateral Therapeutics Inc. (CLTX) and Schering AG
(Germany)

Generx

Nonsurgical angiogenic gene therapy

Stable exertional angina due to coronary artery disease

Companies plan to initiate two Phase IIb/III trials (6/18)

Corvas International Inc. (CVAS)

Nematode

Injectable anticoagulant, recombinant Nematode Anticoagulant Protein c2

Elective percutaneous transluminal coronary angioplasty

Company completed enrollment in its Phase IIa study (6/6)

CV Therapeutics Inc. (CVTX)

CVT-510

A selective A1 adenosine receptor agonist

Paroxysmal supraventricular tachycardia

Company initiated a Phase III trial (6/29)

The Medicines Co. (MDCO)

Angiomax

Bivalirudin; anticoagulant

Patients undergoing angioplasty

Phase IIIb/IV results showed patients receiving Angiomax experienced fewer complications than patients receiving heparin (6/8)

Valentis Inc. (VLTS)

VLTS-589

Human Del-1 gene medicine for angiogenesis

Peripheral arterial disease

Company initiated patient enrollment in a Phase I/II study (6/13)

Vasogen Inc. (Canada; AMEX:MEW; TSE:VAS)

¿

Immune modulation therapy

Congestive heart failure

Company completed patient enrollment in a clinical trial (6/26)

CENTRAL NERVOUS SYSTEM

Axonyx Inc. (AXYX)

Phenserine

Highly selective and reversible inhibitor of the enzyme acetylchol- inesterase

Alzheimer's disease

Company completed patient enrollment in its Phase II trial (6/28)

Drug Royalty Corp. Inc. (Canada; TSE:DRI) and
Cambridge Anti-
body Technology
Group plc
(UK;
CATG; LSE:CAT)

D2E7

Fully human monoclonal antibody tested in combination with methotrexate

Rheumatoid arthritis

All three doses reduced the signs and symptoms of RA in a study involving 271 patients (6/21)

Durect Corp. (DRRX)

Chronogesic (formerly DUROS sufentanil)

Three-month continuous infusion subcutaneous implant

Chronic pain

Phase II results were positive (6/29)

Interferon Sciences Inc. (OTC BB:IFSC)

Alferon N

Interferon alfa-n3

Multiple sclerosis

Company presented positive results showing two out of 31 patients in the treatment group had gadolinium-enhanced lesions in the brain, while 14 out of 38 patients did in the untreated group (6/26)

NicOx SA (France; Nouveau Marche: NICOX)

NCX 701

Nitric oxide-releasing derivative of paracetamol (acetaminophen)

Pain and fever

Positive Phase I results showed the drug to be well tolerated and absorbed at all doses tested (6/27)

Repligen Corp. (RGEN)

¿

Human synthetic secretin

Autism

Company initiated an open-label extension of the Phase II trial in children who failed to reach the trial's primary endpoint (6/19)

Serono SA (Switzerland; NYSE:SRA)

Rebif

Recombinant interferon beta-1a

Relapsing- remitting multiple sclerosis

Results presented showed Rebif patients had a 90% greater chance of remaining relapse-free relative to patients treated with Biogen Inc.'s Avonex, which has orphan drug status; Biogen disputed finding (6/22)

Shire Pharmaceuticals Group plc (UK)
and Cortex
Pharmaceuticals
Inc.
(AMEX:COR)

CX516

Ampakine CX516

Attention deficit hyperactivity disorder

Companies will initate enrollment in a Phase II study (6/13)

Symbollon Pharmaceuticals Inc. (SYMBA)

IoGen

Molecular iodine

Pain and tenderness associated with fibrocystic breast disease

Company expects to begin enrolling patients in a Phase III trial in the first quarter of 2002 (6/26)

DIABETES

Alkermes Inc. (ALKS)

Inhaled insulin

Based on Alkermes' AIR pulmonary drug delivery system

Diabetes

Phase I data showed a rapid onset of therapeutic action, dose-dependent glucose-lowering ability and competitive biopotency (6/25)

Amylin Pharmaceuticals Inc. (AMLN)

AC2993

Synthetic exendin-4

Diabetes

Company said AC2993 produced a statistically significant lowering of fructosamine in a 28-day study and all dosing arms achieved a statistically significant improvement in glycated hemoglobin levels (6/20); company said the data support progression of AC2993 into Phase III (6/25)

DepoMed Inc. (AMEX:DMI)

Metformin GR

Once-daily treatment that uses DepoMed's gastric retention technology

Type II diabetes

Company started a Phase III trial (6/21)

Inhale Therapeutic Systems Inc. (INHL)

Exubera

Inhaled insulin

Type I and Type II diabetes

Phase III data showed more patients treated with inhaled insulin achieved the recommended blood glucose levels than patients who received only insulin injections (6/25)

Nobex Corp.*

¿

Oral insulin product

Type I and Type II diabetes

Phase II results showed positive safety and efficacy trends (6/26)

INFECTION

CV Technologies Inc. (Canada;
CDNX:CVQ)

CVT-E002

A multicomponent phytopharmaceutical

Upper respiratory infections

Company completed a Phase II trial (6/26)

Gilead Sciences Inc. (GILD)

Adefovir dipivoxil

Antiviral reverse transcriptase inhibitor

Naove chronic hepatitis B

Interim Phase III data of adefovir dipivoxil showed no resistance mutations and met its endpoints of liver histology improvement; it also showed no kidney toxicity (6/22)

GenStar Therapeutics (AMEX:GNT)

Maximum-AD

Engineered to optimize Factor VIII expression in the liver

Hemophilia A

Company initiated a Phase I gene therapy trial (6/18)

Hemispherx Biopharma Inc. (AMEX:HEB)

Ampligen

Double-stranded synthetic RNA compound poly 1; poly C124

HIV

Company commenced treatment cycles in two new Phase IIb trials with Ampligen, designed to overcome and/or prevent multidrug-resistant HIV (6/14)

Isis Pharmaceuticals Inc. (ISIP)

ISIS 14803

Antisense drug; 20-base phosphorothioate oligonucleotide

Drug-resistant chronic hepatitis C

A Phase I/II trial with 11 patients demonstrated dose-dependent antiviral activity (6/18)

Palatin Technologies Inc. (AMEX:PTN)

LeuTech

Radiolabeled monoclonal antibody intended to image and diagnose sites of infection

Osteomyelitis

Phase II results showed LeuTech to be well tolerated and superior to both indium oxine-labeled white blood cells and 3-phase bone scans (6/25)

Transkaryotic Therapies Inc. (TKTX)

Factor VIII

Gene therapy

Hemophilia A

Phase I results showed the nonviral ex vivo gene therapy system delivering Factor VIII was safe and well tolerated (6/6)

Trimeris Inc. (TRMS)

T20

Fusion inhibitor

HIV

Completed patient enrollment in a Phase III trial (6/28)

Versicor Inc. (VERS)

Anidulafungin

Intravenous infusion

Candidiasis/ candidemia

Company started a Phase II trial (6/26)

MISCELLANEOUS

Adolor Corp. (ADLR)

ADL8-2698

Gastrointestinal tract- restricted opioid narcotic antagonist

Bowel dysfunction

Phase II trial showed positive results (6/29)

Alexion Pharmaceuticals Inc. (ALXN)

5G1.1

Humanized monoclonal antibody C5 complement inhibitor

Lupus nephritis

Company began a Phase II trial (6/7)

Genentech Inc. (NYSE:DNA)
and XOMA Ltd.
(XOMA)

Xanelim

Humanized monoclonal antibody

Psoriasis

Phase III trial results were positive (6/21)

Genzyme General (GENZ)

Renagel

Calcium-based phosphate binders to control serum phosphorous levels

End-stage renal disease

Data from a three-year trial showed patients experienced a 25% increase in their coronary artery calcification scores after one year of taking calcium-based phosphate binders, while patients taking Renagel experienced a 6% increase (6/26)

InKine Pharmaceutical Co. Inc. (INKP)

Colirest

Oral steroid molecule; Fc receptor technology

Crohn's disease

Company enrolled the first patient for treatment in the pivotal Phase II trial (6/25)

Isis Pharmaceuticals
Inc.
(ISIP)

ISIS 104838

Inhibitor of tumor necrosis factor-alpha

Psoriasis

Company initiated a Phase II trial (6/21)

ISTA Pharmaceuticals Inc. (ISTA)

Vitrase

Injectable enzyme; hyaluronidase

Vitreous hemorrhage

Company completed patient patient enrollment in one of two Phase III trials (6/28)

Lilly ICOS LLC (joint venture of ICOS Corp. [ICOS]
and Eli Lilly and Co.)

Cialis

Inhibits PDE5

Erectile dysfunction

Phase III results showed 85% of patients experienced improved erections (6/1)

Lilly ICOS LLC (joint venture of ICOS Corp. [ICOS]
and Eli Lilly and Co.)

IC351

Inhibits cGMP-destroying enzyme PDE5

Female sexual arousal disorder

Trial results showed no conclusive treatment effect relative to placebo (6/18)

MedImmune Inc. (MEDI) and BioTransplant
Inc.
(BTRN)

MEDI-507

Siplizumab

Psoriasis

Phase I and Phase I/II trial results showed the drug was generally safe and well tolerated (6/25)

Millennium Pharmaceuticals Inc. (MLNM)

LDP-977

Orally active second- generation 5-lipoxygenase inhibitor

Asthma

Company initiated a Phase II trial (6/12)

Miravant Medical
Technologies
Inc.
(MRVT)

MV9411

PhotoPoint drug

Skin disorders

Company completed enrollment in the Phase I trial (6/14)

Nastech Pharmaceutical Co. (NSTK)

Apomorphine

Intranasal formulation

Erectile dysfunction

Interim Phase II results indicated a dose of the drug allowed successful intercourse 80% of the time (6/5)

Nastech Pharmaceutical
Co.
(NSTK)

Apomorphine

Intranasal formulation

Female sexual dysfunction

Company initiated a Phase II at-home trial in 75 women (6/12)

NeoTherapeutics Inc. (NEOT)

Neotrofin

Nerve regeneration drug

Spinal cord

Company expanded its Phase II trial (6/29)

NexMed Inc. (NEXM)

Alprox-TD

Cream that combines alprostadil and NexACT transdermal deliverytechnology

Erectile dysfunction

Phase II results showed the cream produced between a 59% and an 83% improvement in erections (6/4)

SangStat Inc. (SANG)

RDP58

Novel peptide that inhibits tumor necrosis factor synthesis

Inflammation

Company initiated a Phase I study (6/18)

Sepracor Inc. (SEPR)

(S)oxybutynin

Sustained-release formulation

Overactive bladder

Company initiated a 12-week Phase III study with 850 patients (6/20)

Texas Biotechnology
Corp.
(TXBI)

Biomosiamose

Inhaled formulation; a selectin antagonist

Asthma

Phase I trial was initiated (6/26)

Theratechnologies Inc. (Canada;
TSE:TH)

ThGRF

Peptide; a growth hormone-releasing factor analogue

Insomnia

Company began enrollment for its second Phase II trial (6/27)

Zonagen Inc. (ZONA)

Bimexes

Combination oral product

Impotence

Phase II results comparing the product to Viagra showed no statistically significant differences (6/13)

Zonagen Inc. (ZONA)

ERxin

Penile injection product

Impotence

Phase II results indicated the treatment with a bimix of phentolamine and prostaglandin or a trimix containing ohentolamine, papavarine and prostaglandin produced erections in 43% of test subjects at the lowest dose (6/20)


Notes:

* Privately held

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange

No Comments